Challenges in immunodiagnostic tests for leprosy

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 3, 2013, Pages 265-274

  Geluk, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Cytokines; Early diagnosis; Field friendly assays; Leprosy; M. leprae; Recombinant proteins

Indexed keywords

BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; CELL ASSAY; CELLULAR IMMUNITY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EXPOSURE; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; INNATE IMMUNITY; LEPROSY; LEPROSY CONTROL; NONHUMAN; REVIEW; RISK FACTOR; SEROLOGY; TH1 CELL; EARLY DIAGNOSIS; IMMUNOASSAY; IMMUNOLOGY;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; IMMUNOASSAY; LEPROSY;

EID: 84876838070     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.786039     Document Type: Review

References (110)

1. Stoner GL. Importance of the neural predilection of Mycobacterium leprae in leprosy. Lancet 1979;2:994-6
2. Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev 2006;19:338-81
3. Rodrigues LC, Lockwood DN. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011;11:464-70
4. Leprosy update, 2011. Wkly Epidemiol Rec 2011;86:389-99
5. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A fivegroup system. Int J Lepr Other Mycobact Dis 1966;34:255-73
6. Kaplan G, Cohn ZA. Leprosy and cell-mediated immunity. Curr Opin Immunol 1991;3:91-6
7. Modlin RL, Melancon-Kaplan J, Young SM, et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci USA 1988;85:1213-17
8. Fava V, Orlova M, Cobat A, et al. Genetics of leprosy reactions: an overview. Mem Inst Oswaldo Cruz 2012;107(Suppl 1):132-42
9. Alter A, Grant A, Abel L, et al. Leprosy as a genetic disease. Mamm Genome 2011;22:19-31
10. Misch EA, Macdonald M, Ranjit C, et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis 2008;2:e231
11. Bochud PY, Hawn TR, Siddiqui MR, et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008;197:253-61
12. Mira MT, Alcais A, di Pietrantonio T, et al. Segregation of HLA/TNF region is linked to leprosy clinical spectrum in families displaying mixed leprosy subtypes. Genes Immun 2003;4:67-73
13. Vanderborght PR, Pacheco AG, Moraes ME, et al. HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun 2007;8:320-4
14. Ottenhoff TH, de Vries RR. HLA class II immune response and suppression genes in leprosy. Int J Lepr Other Mycobact Dis 1987;55:521-34
15. Geluk A, Ottenhoff TH. HLA and leprosy in the pre and postgenomic eras. Hum Immunol 2006;67:439-45
16. Mira MT, Alcais A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004;427:636-40
17. Alcais A, Alter A, Antoni G, et al. Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy. Nat Genet 2007;39:517-22
18. Pereira AC, Brito-de-Souza VN, Cardoso CC, et al. Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in leprosy susceptibility. Genes Immun 2009;10:174-80
19. Sapkota BR, Macdonald M, Berrington WR, et al. Association of TNF, MBL, and VDR polymorphisms with leprosy phenotypes. Hum Immunol 2010;71:992-8
20. Siddiqui MR, Meisner S, Tosh K, et al. A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nat Genet 2001;27:439-41
21. Jamieson SE, Miller EN, Black GF, et al. Evidence for a cluster of genes on chromosome 17q11-q21 controlling susceptibility to tuberculosis and leprosy in Brazilians. Genes Immun 2004;5:46-57
22. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med 2009;361:2609-18
23. Liu PT, Wheelwright M, Teles R, et al. MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med 2012;18:267-73
24. Geluk A, Bobosha K, van der Ploeg-van Schip JJ, et al. New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol 2012;188:4782-91
25. World Health Organization. WHO expert committee on leprosy. World Health Organ Tech Rep Ser 2012(968):1-61.1
26. Smith C, Richardus JH. Leprosy strategy is about control, not eradication. Lancet 2008;371:969-70
27. Barreto ML, Teixeira MG, Bastos FI, et al. Successes and failures in the control of infectious diseases in Brazil: social and environmental context, policies, interventions, and research needs. Lancet 2011;377:1877-89
28. Barreto JG, Guimaraes LS, Frade MA, et al. High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon Region. Mem Inst Oswaldo Cruz 2012;107(Suppl 1):60-7
29. Koster FT, Scollard DM, Umland ET, et al. Cellular and humoral immune response to a phenolic glycolipid antigen (PhenGL-I) in patients with leprosy. J Clin Microbiol 1987;25:551-6
30. Young DB, Dissanayake S, Miller RA, et al. Humans respond predominantly with IgM immunoglobulin to the species-specific glycolipid of Mycobacterium leprae. J Infect Dis 1984;149:870-3
31. Spencer JS, Brennan PJ. The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. Lepr Rev 2011;82:344-57
32. Stefani MM, Grassi AB, Sampaio LH, et al. Comparison of two rapid tests for anti-phenolic glycolipid-I serology in Brazil and Nepal. Mem Inst Oswaldo Cruz 2012;107(Suppl 1):124-31
33. Silva RC, Lyon S, Araos R, et al. The result patterns of ML Flow and ELISA (PGL-I) serologic tests in leprosy-endemic and non-endemic areas. Rev Soc Bras Med Trop 2008;41(Suppl 2):19-22
34. Buhrer-Sekula S, Smits HL, Gussenhoven GC, et al. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol 2003;41:1991-5
35. van Beers SM, Hatta M, Klatser PR. Patient contact is the major determinant in incident leprosy: implications for future control. Int J Lepr Other Mycobact Dis 1999;67:119-28
36. Douglas JT, Cellona RV, Fajardo TT Jr, et al. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diagn Lab Immunol 2004;11:897-900
37. Moet FJ, Oskam L, Faber R, et al. A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. Lepr Rev 2004;75:376-88
38. Goulart IM, Goulart LR. Leprosy: diagnostic and control challenges for a worldwide disease. Arch Dermatol Res 2008;300:269-90
39. Barreto JG, Guimaraes LS, Leao MR, et al. Anti-PGL-I seroepidemiology in leprosy cases: household contacts and school children from a hyperendemic municipality of the Brazilian Amazon. Lepr Rev 2011;82:358-70
40. Spencer JS, Kim HJ, Wheat WH, et al. Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. Clin Vaccine Immunol 2011;18:260-7
41. Geluk A, Duthie MS, Spencer JS. Postgenomic Mycobacterium leprae antigens for cellular and serological diagnosis of M. leprae exposure, infection and leprosy disease. Lepr Rev 2011;82:402-21
42. Hungria EM, Oliveira RM, Souza AL, et al. Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil. Mem Inst Oswaldo Cruz 2012;107(Suppl 1):104-11
43. Spencer JS, Duthie MS, Geluk A, et al. Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz 2012;107(Suppl 1):79-89
44. Duthie MS, Goto W, Ireton GC, et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol 2007;14:1400-8
45. Duthie MS, Ireton GC, Kanaujia GV, et al. Selection of antigens and prototype test development for a point-of-care leprosy diagnosis. Clin Vaccine Immunol 2008;15(10):1590-7
46. Silva EA, Iyer A, Ura S, et al. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health 2007;12:1450-8
47. Lockwood DN, Suneetha L, Sagili KD, et al. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis 2011;5:e1327
48. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, et al. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002;32:97-105
49. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012;8:e1002607
50. Montoya D, Modlin RL. Learning from leprosy: insight into the human innate immune response. Adv Immunol 2010;105:1-24
51. Chaitanya S, Lavania M, Turankar RP, et al. Increased serum circulatory levels of interleukin 17F in type 1 reactions of leprosy. J Clin Immunol 2012;32:1415-20
52. Martiniuk F, Giovinazzo J, Tan AU, et al. Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. J Drugs Dermatol 2012;11:626-30
53. Palermo ML, Pagliari C, Trindade MA, et al. Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am J Trop Med Hyg 2012;86:878-83
54. Modlin RL, Kato H, Mehra V, et al. Genetically restricted suppressor T-cell clones derived from lepromatous leprosy lesions. Nature 1986;322:459-61
55. Ottenhoff TH, Haanen JB, Geluk A, et al. Regulation of mycobacterial heat-shock protein-reactive T cells by HLA class II molecules: lessons from leprosy. Immunol Rev 1991;121:171-91
56. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010;375:1920-37
57. Ruhwald M, Dominguez J, Latorre I, et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) 2011;91:260-7
58. Aabye MG, Ruhwald M, Praygod G, et al. Potential of interferon-gamma- inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur Respir J 2010;36:1488-90
59. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature 2001;409:1007-11
60. Geluk A, van Meijgaarden KE, Franken KL, et al. Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infect Immun 2002;70:2544-8
61. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328-34
62. Geluk A, van Meijgaarden KE, Franken KL, et al. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis. Scand J Immunol 2004;59:66-70
63. Dockrell HM, Brahmbhatt S, Robertson BD, et al. A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents. Infect Immun 2000;68:5846-55
64. Geluk A, Klein MR, Franken KL, et al. Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection. Infect Immun 2005;73:5636-44
65. Spencer JS, Dockrell HM, Kim HJ, et al. Identification of specific proteins and peptides in mycobacterium leprae suitable for the selective diagnosis of leprosy. J Immunol 2005;175:7930-8
66. Araoz R, Honore N, Banu S, et al. Towards an immunodiagnostic test for leprosy. Microbes Infect 2006;8:2270-6
67. Geluk A, Spencer JS, Bobosha K, et al. From genome-based in silico predictions to ex vivo verification of leprosy diagnosis. Clin Vaccine Immunol 2009;16:352-9
68. Sampaio LH, Stefani MM, Oliveira RM, et al. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis 2011;11:26
69. Geluk A, van der Ploeg-van Schip JJ, Teles RO, et al. Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection. Clin Vaccine Immunol 2008;15:522-33
70. Lahiri R, Randhawa B, Franken KL, et al. Development of a mouse food pad model for detection of sub clinical leprosy. Lepr Rev 2011;82:432-44
71. Pena M, Geluk A, van der Ploeg-van Schip JJ, et al. Cytokine responses to Mycobacterium leprae unique proteins differentiate between Mycobacterium leprae infected and naive armadillos. Lepr Rev 2011;82:422-31
72. Martins MV, Guimaraes MM, Spencer JS, et al. Pathogen-specific epitopes as epidemiological tools for defining the magnitude of Mycobacterium leprae transmission in areas endemic for leprosy. PLoS Negl Trop Dis 2012;6:e1616
73. Bobosha K, van der Ploeg-van Schip JJ, Esquenazi DA, et al. Peptides derived from Mycobacterium leprae ML1601c discriminate between leprosy patients and healthy endemic controls. J Trop Med 2012;2012:132049
74. Bobosha K, Tang ST, van der Ploeg-van Schip JJ, et al. Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal. Mem Inst Oswaldo Cruz 2012;107(Suppl 1):112-23
75. Montoya D, Cruz D, Teles RM, et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 2009;6:343-53
76. Ottenhoff TH, Dass RH, Yang N, et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One 2012;7:e45839
77. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophildriven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-7
78. Joosten SA, Goeman JJ, Sutherland JS, et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun 2012;13:71-82
79. Sampaio LH, Sousa AL, Barcelos MC, et al. Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy. Eur J Clin Microbiol Infect Dis 2012;31:1443-51
80. Verreck FA, de Boer T, Langenberg DM, et al. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFNgamma-and CD40L-mediated costimulation. J Leukoc Biol 2006;79:285-93
81. van der Does AM, Beekhuizen H, Ravensbergen B, et al. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol 2010;185:1442-9
82. Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012;20:419-28
83. Dorhoi A, Reece ST, Kaufmann SH. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol Rev 2011;240:235-51
84. Kurtz J. Specific memory within innate immune systems. Trends Immunol 2005;26:186-92
85. Roth O, Kurtz J. Phagocytosis mediates specificity in the immune defence of an invertebrate, the woodlouse Porcellio scaber (Crustacea: isopoda). Dev Comp Immunol 2009;33:1151-5
86. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 2013;13:88-100
87. Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 2003;10:247-57
88. de Leseleuc L, Orlova M, Cobat A, et al. PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages. PLoS Negl Trop Dis 2013;7:e2015
89. Joosten SA, van Meijgaarden KE, Savage ND, et al. Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 2007;104:8029-34
90. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004;36:1882-6
91. Iwasaki A. The importance of CD11b+ dendritic cells in CD4+ T cell activation in vivo: with help from interleukin 1. J Exp Med 2003;198:185-90
92. Mayer-Barber KD, Barber DL, Shenderov K, et al. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010;184:3326-30
93. Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013;207:18-29
94. Corstjens PL, de Dood CJ, van der Ploeg-van Schip JJ, et al. Lateral flow assay for simultaneous detection of cellular-and humoral immune responses. Clin Biochem 2011;44:1241-6
95. Corstjens PL, Zuiderwijk M, Tanke HJ, et al. A user-friendly, highly sensitive assay to detect the IFN-gamma secretion by T cells. Clin Biochem 2008;41:440-4
96. Duthie MS, Hay MN, Rada EM, et al. Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. Eur J Clin Microbiol Infect Dis 2011;30(10):1257-65
97. Stefani MM, Guerra JG, Sousa AL, et al. Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect Dis 2009;9:75
98. Rodrigues LS, Hacker MA, Illarramendi X, et al. Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy. BMC Infect Dis 2011;11:339
99. Scollard DM, Chaduvula MV, Martinez A, et al. Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions. Clin Vaccine Immunol 2011;18:947-53
100. Lockwood DN, Lambert SM. Human immunodeficiency virus and leprosy: an update. Dermatol Clin 2011;29:125-8
101. Talhari C, Mira MT, Massone C, et al. Leprosy and HIV coinfection: a clinical, pathological, immunological, and therapeutic study of a cohort from a Brazilian referral center for infectious diseases. J Infect Dis 2010;202:345-54
102. Massone C, Talhari C, Ribeiro-Rodrigues R, et al. Leprosy and HIV coinfection: a critical approach. Expert Rev Anti Infect Ther 2011;9:701-10
103. Kwobah CM, Wools-Kaloustian KK, Gitau JN, Siika AM. Human immunodeficiency virus and leprosy coinfection: challenges in resource-limited setups. Case Rep Med 2012;2012:698513
104. Talhari S, Grossi MA, de Oliveira ML, et al. Hansen's disease: a vanishing disease? Mem Inst Oswaldo Cruz 2012;107(Suppl 1):13-16
105. Diniz LM, Magalhaes EF, Pereira FE, et al. Presence of intestinal helminths decreases T helper type 1 responses in tuberculoid leprosy patients and may increase the risk for multi-bacillary leprosy. Clin Exp Immunol 2010;161:142-50
106. Saraya MA, Al-Fadhli MA, Qasem JA. Diabetic status of patients with leprosy in Kuwait. J Infect Public Health 2012;5:360-5
107. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 2012;7:e46191
108. Smith SG, Lecher S, Blitz R, et al. Broad heparin-binding haemagglutinin-specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination. Eur J Immunol 2012;42:2511-22
109. Chegou NN, Black GF, Kidd M, et al. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009;9:21
110. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009;17:183-8